Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-gamma for sepsis-induced immunoparalysis
2012-002491-14Phase 3Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immunologic paralysis, septic shock, sepsis and 1 more comparing Recombinant human interferon-gamma plus standard therapy with Placebo plus standard therapy (2 arms). Started Jul 2012; status: terminated.
02
Drugs
interferon gamma-1b
03
Conditions
immunologic paralysisseptic shocksepsisSystemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on 2012-002491-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002491-14.